ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09FDA-cleared profile
Siemens Healthcare GmbH · CT/CTA · FDA-cleared (510(k))
Authorized purpose: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Evidence takeaway. Evidence from the reviewed source record: The pivotal retrospective reader study had 20 readers review all 232 cases in both second-reader and concurrent-first-reader workflows; five expert radiologists reviewed consolidated marks. Reader-majority truthing with expert adjudication identified 143 cases with at least one true nodule and 89 without true nodules. All reported analysis endpoints were satisfactorily met and all readers showed significant improvement in detection of solid, part-solid, and ground-glass nodules in both workflows; no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta result is provided in the packet text.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
This field has not been curated yet.
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Chest MDCT from multivendor scanners, with 16 or more detector rows; the scan must cover the entire thorax from lung apices to bases, with cranio-caudal or caudal-cranial direction, 100-140 kVp, up to and including 2.5 mm slice thickness, and no reconstruction gaps. The packet describes Siemens, GE, Philips, and Toshiba scanner data and typical validated kernels.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD
Source context, not route validation: The algorithm sends candidate locations to a hosting visualization application such as syngo MM Oncology or a rendering component; syngo MM Oncology is deployed on syngo.via, which displays the CAD marks. The device has no standalone UI, and specific local PACS or RIS compatibility is not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD
Source context, not route validation: The exact FDA package describes syngo.CT Lung CAD as an algorithm without its own user interface, incorporated in a hosting application (syngo MM Oncology) on the syngo.via hosting platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The software device is an algorithm which does not have its own user interface component for displaying of CAD marks. The Hosting Application incorporating syngo.CT Lung CAD is responsible for implementing a user interface." … "Hosting Platform syngo.via (VB50) syngo.via (VB60)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 · FDA K203258: syngo.CT Lung CAD
Source context, not route validation: A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD
Unresolved route: A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-09 · FDA K203258: syngo.CT Lung CAD
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Packet wording: "The software device is an algorithm which does not have its own user interface component for displaying of CAD marks. The Hosting Application incorporating syngo.CT Lung CAD is responsible for implementing a user interface." … "Hosting Platform syngo.via (VB50) syngo.via (VB60)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public price or quote for the exact K203258 configuration was established in this review.
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
8 sources - 3 history items
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment
Scope: regulatoryIdentity, modalityContext
Scope: anatomy
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: postmarketSafety
Scope: security
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Fujifilm Corporation
Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
Median Technologies
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Precision Medical Ventures, Inc. Dba Revealdx
Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening
Infervision Medical Technology Co., Ltd.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history